Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, we establish the molecular mechanisms underlying molnupiravir-induced RNA mutagen...
Alternative Titles
Full title
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8437801
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8437801
Other Identifiers
ISSN
1545-9993,1545-9985
E-ISSN
1545-9985
DOI
10.1038/s41594-021-00651-0
